Obstetrics, gynecology and reproductive medicine guidelines

Urogynecology, urinary and fecal incontinence

PubMed Free Full Text

Overactive bladder

 

Australia

• Australian Family Physician
  • Overactive bladder syndrome – management and treatment options [2012]

• Medical Services Advisory Committee
  • Transurethral Injection of Botulinum Toxin into the Bladder Wall for Urinary Incontinence due to Neurogenic Detrusor Overactivity [2012]

Canada

• Canadian Agency for Drugs and Technologies in Health
  • The Use of the Electromotive Drug Administration System in Patients with Overactive Bladder: A Review of the Clinical Effectiveness, Safety, and Cost-Effectiveness [2014]

Cochrane

• Cochrane Library
  • Which anticholinergic drug for overactive bladder symptoms in adults
  • Electrical stimulation with non-implanted electrodes for overactive bladder in adults
  • Botulinum toxin injections for adults with overactive bladder syndrome
  • Anticholinergic drugs versus placebo for overactive bladder syndrome in adults
  • Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults

Europe

• European Association of Urology
  • Dealing with complex overactive bladder syndrome patient profiles with focus on fesoterodine: in or out of the EAU guidelines? [2017]

France

• Progrès en Urologie
  • Guidelines for practical usage of botulinum toxin type A (BoNTA) for refractory idiopathic overactive bladder management: Translation of French recommendations [2014]

Turkey

• Turkish Journal of Urology
  • The attitudes of Urologists and Gynecologists about overactive bladder and treatment of it in Turkey: A questionnaire survey [2017]

United Kingdom

• Health Technology Assessment
  • Bladder ultrasonography for diagnosing detrusor overactivity: test accuracy study and economic evaluation [2016]

• Journal of Clinical Urology
  • Botulinum toxin-A for the treatment of overactive bladder: UK contributions [2013]

• National Guideline Clearinghouse
  • Mirabegron for treating symptoms of overactive bladder. National Institute for Health and Care Excellence (NICE) [2013]

• National Institute for Health and Care Excellence
  • Mirabegron for treating symptoms of overactive bladder [2013]
  • Percutaneous posterior tibial nerve stimulation for overactive bladder syndrome [2010]

• NHS England
  • Sacral Nerve Stimulation for Overactive Bladder [2015]

• Royal College of Obstetricians and Gynaecologists
  • Botulinum Toxin for an Overactive Bladder [2014]

United States of America

• Agency for Healthcare Research and Quality
  • Treatment of Overactive Bladder in Women [2009]

• American Congress of Obstetricians and Gynecologists
  • OnabotulinumtoxinA and the Bladder [2014]

• American Urological Association
  • Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline [2014]

• National Guideline Clearinghouse
  • Management of Overactive Bladder (OAB) [Guideline synthesis]
  • Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline [2014]

Articles in journals

• Australian Family Physician
  • Comparison of efficacy and tolerability of pharmacological treatment for the overactive bladder in women: A network meta-analysis [2017]

• BMJ Open
  • Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison [2016]

• Toxins
  • Botulinum toxin A for the Treatment of Overactive Bladder [2016]

{Related topics}

• Guidelines
  • Urinary incontinence